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Oestradiol regulation of the components of the
plasminogen-plasmin system in MDA-MB-231 human
breast cancer cells stably expressing the oestrogen
receptor
AS Levenson, HC Kwaan, KM Svoboda, IM Weiss, S Sakurai and VC Jordan
Robert H Lurie Cancer Center, and Division of Hematology/Oncology, Department of Medicine, Nortwestern University Medical School; VA Lakeside Medical
Center, Chicago, IL 60611, USA
Summary To understand the hormonal regulation of the components of the plasminogen-plasmin system in human breast cancer, we
examined the oestradiol (E2) regulaton of plasminogen activators (PAs), namely urokinase-type plasminogen activator (uPA) and tissue-type
plasminogen activator (tPA), plasminogen activator inhibitor type 1 (PAI-1) and uPA receptor (uPAR), in our model system. We used stable
transfectants of the MDA-MB-231 human breast cancer cells that express either the wiki-type (S30 cells) or the mutant 351a ,! oestrogen
receptor (ER) (BC-2 cells). Northem blot analysis showed that there was a concentration-dependent down-regulation of uPA, tPA and PAI-1
mRNAs by E2. In contrast, uPAR mRNA was not modulated by E2. The pure anti-oestrogen ICI 182,780 was able to block E2 action, indicating
that the regulation of these genes is ER mediated. The E2 also inhibited the expression and secretion of uPA, tPA and PAI-1 proteins as
determined by enzyme-linked immunosorbent assay (ELISA) in cell extracts (CEs) and conditioned media (CM). Zymography of the CM
confirmed the inhibitory effect of E2 on uPA activity. Thus, we now report the regulation of uPA, PAI-1 and tPA by E2 in both mRNA and protein
levels in ER transfectants. The association between down-regulation of the uPA by E2 and known E2-mediated growth inhibition ofthese cells
was also explored. Our findings indicate that down-regulation of uPA by E2 is an upstream event of inhibitory effects of E2 on growth of these
cells as the addition of exogenous uPA did not block the growth inhibition by E2.
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The role of components of the plasminogen-plasmin system in
tumour growth. invasion and metastasis is well documented
(Kwaan. 1992: Schmitt et al. 1992). Tumour cell invasion is
accomplished by the concerted action of several extracellular
proteolytic enzyme systems. one of which is the plasminogen-
plasmin system. The different components of this system. e.g.
urokinase-type plasminogen activator (uPA). its receptor (uPAR).
tissue-type plasminogen activator (tPA) and the plasminogen
activator inhibitor type 1 (PAI-1), along with other proteolytic
enzymes. are involved in the process ofactivation ofplasminogen
to plasmin, which, directly or indirectly through the activation of
other matrix metalloproteinases, degrade most components of the
extracellular matrix and basement membrane.
The uPA/uPAR system plays a key role in tumour cell invasion
and dissemination (Dan0 et al. 1985: Kwaan. 1992). Binding of
both double chain uPA (tcuPA) and single-chain uPA (scuPA) to its
receptor (uPAR) with the concomitant cell-surface binding of
plasminogen enhances plasmin generation (Ellis et al. 1991). uPA-
mediated proteolysis is modulated by PAI-1. the inhibitor for both
uPA and tPA. PAI-I binding to receptor-bound uPA results in
internalization of the uPA/PAI-l complexes (Olson et al. 1992).
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Whether the uPAR is intemalized at the same time (Bastholm et al.
1994) or the receptor just plays an enhancing role in internaliza-
tion (Olson et al. 1992) is not clear.
In carcinoma of the breast, the level of uPA antigen. but not
tPA antigen. in tumour homogenates was found to be a strong
unfavourable prognostic factor for relapse and overall survival
(Janicke et al, 1989: 1990; Foekens et al. 1992; Sumiyoshi et al,
1992). High PAI-I and uPAR levels have also been found to be
unfavourable (Duffy et al. 1988; Janicke et al. 1990; Foekens et al.
1992; Grondahl-Hansen et al, 1993:1995). Several studies have
found no correlation between high uPA (Grondahl-Hansen et al,
1997), PAI-l or uPAR levels and the oestrogen receptor (ER) status
ofthe tumour (Duggan et al. 1995: Foekens et al. 1995; Gohring et
al, 1995), whereas others (Foekens et al, 1994; Grondahl-Hansen et
al. 1993;1995; Ferno et al. 1996) have demonstrated that high uPA.
PAI-1 and uPAR contents in tumours are negatively correlated with
the ER and progesterone receptor (PgR). In contrast, Duffy and
colleagues (1986) state that levels of tPA activity had the highest
correlation with ER and PgR positivity in human breast carci-
nomas. Determination of uPA levels and. to a lesser extent, PAI-1
levels was found to be useful in predicting the rate of response to
tamoxifen therapy formetastatic disease (Foekens et al. 1995). Cell
lines derived from human carcinoma of breast have also been
studied for the expression of uPA, uPAR. PAI-I and tPA (Butler
et al. 1979; Shyamala and Dickerman. 1982; Huff and Lippman.
1984: Mangel et al, 1988; Madsen and Briand. 1990: Holst-Hansen
et al. 1996) and their role in cancer cell invasion and metastasis
(Madsen and Briand, 1990; Holst-Hansen et al. 1996: Long and
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Rose, 1996). The plasminogen activators' (PAs) activity in ER-
containing human breast cancer cell lines is stimulated by oestra-
diol (E,) and suppressed by anti-oestrogens (Butler et al, 1979;
1993; Shyamala and Dickerman, 1982; Huff and Lippman, 1984;
Katzenellenbogen et al. 1984). Most investigators, with only one
exception (Yang et al, 1983), have found that tPA and not uPA is
regulated by E, in MCF-7 cells (Ryan et al, 1984; Dickerman et al,
1989; Butleretal, 1979; Mizoguchi et al, 1990). On the otherhand,
Mangel et al (1988) have shown that uPA was stimulated by E, in
the T47-D and ZR-75-1 cells containing lower levels of ER,
whereas MDA-MB-231 cells, which do not contain ER, showed a
high level of both PAs activity that was not modulated by E,.
Interactions between oestrogen, tamoxifen and retinoic acid are
alsoreflected in theexpression ofPAsbybreastcancercells (Butler
and Fontana, 1992). PAI-1 levels were not influenced by E, in
MCF-7 culture media (Davis et al, 1995), whereas in endometrial
Ishikawa cells both E, and progesins induced the expression of
PAI-1 and its mRNA (Fujimoto et al, 1996). Thus, in hormone-
dependent breast cancers, dissolution of the extracellular matrx
may be modulated by PAs and PAI-1 underhormonal control.
To understand the hormonal regulation of components ofplas-
minogen-plasmin system, we examined their E, regulation in our
model system, using ER-negative MDA-MB-231 breast cancer
cells transfected with either the wild-type (S30 cells) or the codon
351AsT mutant ER (BC-2 cells). The purpose ofthis study was,
using S30 and BC-2 cell lines, to: (a) examine the oestogen
responsiveness of the components of the plasminogen-plasmin
system, namely uPA, tPA, PAI-1 and uPAR; (b) determine if the
process is ER-mediated; and (c) correlate the oestrogen respon-
siveness ofthe uPA with known growth inhibitory effect ofE, on
these cells.
MATERIALS AND MrETHOS
Cell culture
The MDA-MB-231 clone IOA ER-negative breast cancer cells
were used for stable transfection of either wild-type hER cDNA
(HEGO) or mutant 351ApTr hER cDNA (HETO). S30 cells
(wild-type ER) and BC-2 cells (mutant ER) expressing com-
parable levels of ER were isolated (Jiang and Jordan, 1992;
Catherino et al, 1995). Cells were maintained in phenol red-free
MEM media containing 5% charcoal-stripped calf serum,
penicillin (100 U ml-'), strptomycin (100 ltgml-'), L-glutamine
(2 mM), non-essential amino acids (100 mM), bovine insulin
(6 ng ml-') and G-418 (500tLg ml-'). All materials were obtained
from Gibco BRL, Life Technologies (Gaidtersburg, MD, USA).
Oestradiol was purchased from Sigma Chemical (St Louis, MO,
USA), ICI 182,780 was a generous gift from Dr Alan Wakeling
(Zeneca Pharmaceuticals, Macclesfield, UK), and uPA was kindly
provided by DrJack Henkin (Abbott Laboratories, North Chicago,
IL, USA). The uPA, tPA, PAI-I and uPAR cDNA-containing plas-
mids were obtained from the American Type Culture Collection
(Rockville, MD, USA). Oestradiol and ICI 182,780 were dissolved
in 100% ethanol and added to the media in a 1:1000 dilution for a
final ethanol concentration no greater than 0.2%.
Northem blot analysis
Northern blot analysis was performed as described previously
(Levenson et al, 1997). Briefly, total RNA was isolated from cells
following 48 h of treatment with compounds using the Trizol
Reagent (Gibco, BRL). Twenty micrograms of total RNA sample
was fractionated in 1.2% agarose-formaldehyde gel and trans-
ferred to a nylon membrane (Hybond-N+; Amersham, Arlington
Heights, IL, USA). The membranes were hybridized at 420C with
the corresponding 32P-labelled probes. The membranes were
then washed and autoradiographed by exposure to Hyperfilm
(Amersham) at -8C with intensifying screens. The expected
2.5-kb (uPA), 2.6-kb (tPA), 3.2- and 2.3-kb (PAI-1), and 1.4-kb
(uPAR) tanscripts were detected. Because the sizes of mRNAs
were similar, probing was performed on separate blots for each
gene. Subsequently, the blots were stripped and reprobed with a
cDNA to 1-actin. The signals were quantitated using phosphor-
image analysis (Molecular Dynamics phosphorimager, Image
Quant software).
Enzymelinked immunosorbent assay (ELISA)
Two hundred thousand cells were platedperwell in six-well dishes
in 3 ml of media as described above. The cells were then treated
with 10-9M oestradiol or ethanol (control) for 48 h. Cell extracts
(CEs) were isolated using Camiolo buffer (potassium acetate
75 mM, sodium chloride 300 mM, L-arginine 100 mM, EDTA
10 mM and 0.25% Triton X-100). The conditioned media (CM)
were centrifuged at 5000g and aliquots were stored at-00C until
use. The corresponding cells were counted so that the levels of
proteins could be standardized to the cell number. For the ELISA,
the CM were diluted 1:10, and CEs were diluted 1:50 in PBS
EDTAJTween and samples were analysed for uPA, tPA, PAI-l
antigen levels using the ELISA kits TintElize uPA, tPA or PAI-I
(Biopool, Sweden) with the corresponding antibodies. The uPA
ELISA recognizes the scuPA as well as active tcuPA, whether it is
free, receptorbound orcomplexed with PAI-1. Forthe quantitation
of uPAR as well as uPAR/uPA and uPAR/uPA/PAI-l complexes
the uPAR ELISA kit (American Diagnostica, Greenwich, CT,
USA) was used. All assays were performed as described by the
supplier.
Chromogenic assays
The proteolytic activity of uPA was assayed using a commercial
Chromolize kit (Biopool, Ventura, CA, USA).The CM were added
to a microtest plate well coated with monoclonal antibody against
uPA, enabling the adsorption of uPA to the plate wall. After
washing the non-absorbed material, plasmin was added to the well
for the conversion of all scuPA to the active tcuPA. The uPA
activity was determined by the addition of plasminogen and a
plasmin-sensitive chromogenic substrate (D-But-CHT-Lys-pNA).
uPA converted the plasminogen to plasmin, which reacts with the
chromogenic substrate. This reaction was assayedby measurement
ofthe absorbance at 405 um.
Zymography
uPA, tPA and PAI-1/PA complex activities were analysed using
zymography. Samples were electrphoresed in the presence of
sodium dodecyl sulphate (SDS) underdenaturing but non-reducing
conditions in 10% polyacrylamide gels (SDS-PAGE) using the
buffer system ofLaemmli (1970) by a modification ofthe methods
of Granrelli-Piperno and Reich (1978) and DePetro et al (1984).
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Diagnostica) were applied in each gel. In addition, standards for
uPA/PAI-l complex andfortPA/PAI-l complex wereapplied. They
wereproducedby first activating the 3.5 gg ofPAI-I by boiling for
30 s, cooling slightly, adding excess uPA andtPA, respectively, and
incubating at 37°C for 30min to permitcomplex formation.
Growth assays
Growth assays were performed as described previously (Levenson
et al, 1997). Briefly, cells maintained in the mediadescribed above
were plated at a density of 4x104 cells per well in 24-well plates
and cultured for the 6 days either in media containing different
concentrations of E,, uPA or in combinations. The media were
changed every otherday. Cells were then harvested and sonicated
for 20 s with an ultrasonic cell disrupter. The amount of DNA in
each well was measured by incubating samples with Hoechst
33258 dye for 1 h according to the method described by LaBarca
and Paigen (1980). Fluorescence measurements were performed
using a Sequoia-Turner fluonimeter (Bansteadrfhennolyne,
Dubuque, IA, USA). Points for each of the measurements repre-
sent the mean ± s.e.m. ofthree replicate wells.
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Fijure 1 C regaaion of mRNA expression of
cmponernt ofe systen in S30 cels eated with ET.
Total RNA was isolated 48 h after beatnent with various ccentratons of E2
as descrbed i Mateials and methods. The Northen blot shows the uPA
2.54-b message and the I-ain sia (A); the PAI-1 3.2- and
2.34-b message and te correspordng P-aci signal (B); the tPA 2.64-b
messge and the espcxng actin siegna (C); and the uPAR 1.44-b
message and the correso afin sig (D). The graph shows the
relative [the ratio normalized mRNA levels i cels bted with E2 to the
normralzed mRNA cel treated with ethnl (cono)] as
determied by dtomeic analyses for each gene
After SDS-PAGE, gels were washed twice for 30 min with 2.5%
Triton X-100 in 0.1 M Tris-HCl, pH 8.1, with a gentle rocking
motion, then washed three times in distilled water for 10min. The
gel was then layered over a casein-fibrin agarose indicator gel,
consisting of agarose (17.25 mg ml-', Bio-Rad Laboratories,
Richmond, CA, USA), casein (non-fat dry milk, 42 mg ml-'),
bovine fibrinogen (1.5 mg ml-'), human fibrinogen fragment D
(2 jg ml-'), human thrombin (0.04 U ml-', all from Sigma
Chemical, St Louis, MO, USA) and 20 jig ml-l affinity-purified
human plasminogen (by the method of Deutsch and Mertz, 1970).
The plasminogen activator diffuses into the agargeL converts plas-
minogen to plasmin, resulting in both caseinolysis and fibrinolysis.
The gel was incubated at 37°C for 4-7 h and the zymograph image
was obtained by using ScanJet (Hewlett Packard) and NIH Image
software. The corrsponding standards for uPA and tPA (American
RESULTS
entration-depende regulaton of uPA, tPA, PAIl1
mRNAs butnot uPAR mRNA byE, in S30 cells
To characterize the effect of E, on expression of uPA, tPA, PAI-I
and uPAR mRNA levels in S30 cels, we performed Northem blot
analysis using total RNA from cells teated with various concen-
trations of E, for 48 h. Figure IA shows that expression of uPA
mRNA is down-regulated by E, and that this effect is concentra-
tion dependent. In the presence ofphysiological concentrations of
E, (IO9 M), there was a 3.6-fold decrease in uPA mRNA levels. At
E, concentations of 106 M, the decrease was 7.4-fold. The expres-
sion ofPAT-I mRNA was also down-regulated by E, in a concen-
tration-dependent manner(Figure IB). In the presence of 109 M E,
there was a 1.7-fold decrease in PAI-I mRNA levels compared
with unteated cells. In the case of tPA, the E, effect was even
more pronounced (Figure IC). In the presence of 1X9 M E,, there
was 6.2-fold decrease compared with untreate cells. In contrast,
uPAR mRNA renmained unaffected by E, at any given concentra-
tion (Figure ID). To examine furtherthe E,-mediated repression of
uPA, tPA and PAI-I gene expression we used the pure anti-
oestrogen ICI 182,780 alone and in combination with E, (Figure
2). The compound ICI 182,780 alone did not have any effect on
these mRNA expressions, and in combination with E, was able to
block E,-induced down-regulation ofuPA, PAT-I and tPA mRNAs
(Figure 2A-C). These data suggest that E, regulation ofuPA, tPA
and PAI-I genes occurs through the ER-mediated pathway. Once
again, uPAR mRNA was not affected either by E, or by ICI
182,780 (Figure 2D).
Effect of E2 on expression and secrion of uPA, tPA,
PAM-1 and uPAR in S30 cells
To identify the effect of E, on expression and secretion of uPA,
tPA, PAI-I anduPAR, we performed an ELISA using CEs and CM
from S30 cells in the absence or the presence of 109 M E, for48 h.
The basal levels of uPA in CE varied from 60 to 221 ng mPl.
However, in the presence ofE, cells exhibited a marked decrease
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in uPA levels in all cases. The uPA level when expressed as a ratio
of E, treatment vs baseline was 0.49, indicating that E, has an
inhibitory effect (Figure 3). This inhibitory effect of E, on uPA
production reached statistical significance in CEs (P < 0.005) and
less so in CM because ofthe variability ofCM samples. Assay of
PAI-I showed that E, also decreases levels of PAI-I in both CEs
andCM, but to alesser extent than uPA. ExaminationoftPA levels
also revealed a definite decrease in this protease in expressed
(CEs) and secreted (CM) levels in hormone-trea cells compared
with controls (Figure 3). By contrast, the uPAR levels in these
cells were unaffected by E, treatment.
Effect of E2 on the PAs wctty in BC-2 cells
We performed SDS-PAGE followed by zymography to examine
the effect of E. on the activity of uPA and tPA in the media
conditioned by cells in the absence and the presence of I09 M E,
(Figure 4A). uPA activity was decreased under E, influence
(lane 4) when compared with the control (lane 3); it was not
affected or even increased by ICI 182,780 alone (lane 5),
whereas a minimal decrease in uPA activity was seen with the
El + ICI 182,780 combination (lane 6) because ofthe limitations
of the method& Zymography is semiquantitative, so we also
performed a chromogenic assay, a quantitative method for
measuring the PA activity in the same samples. This method
confirmed the finding of the inhibitory effect of E, on uPA
activity and also demonstrated the ability of ICI 182,780 to
block the effect of E2 (Figure 4B). Although the tPA activity
produced by BC-2 cells is low, a similar pattem of the effect of
E2 and ICI 182,780 was seen. Likewise, the uPAlPAI-l and
tPA/PAI complexes showed similar activities under analogous
conditions.
01Brith Journal ofCancer(1998) 78(1), 88-95
o
-
0 0
'0
e
c
0
e
0.
.-
- - - - - - - - - - - - - - - -
0CancerResearchCampaign 199692 AS Levenson etal
A
1 2 3 4 5 6 7 8
:.. -.e:si
PA1 'OMA- I 1MP1
0 a pl_
1PA *
uPA*
B
i
0
0C
Ia-
c -
0 +
c)
Figure 4 (A) Zymographic analysis of samples of CM for te demonstrato
of the respective activies of uPA, tPA and complexes of uPAJPAI-1 and
tPA/PAI-1. The different samples were obtained from cultures of BC-2 cells
after 48 h of treatment with 109- M E2, 106 M ICI 182,780 and acombination
of E2 and ICI 182,780 (at 10-9 M and 10-6 M). From the left to the rit Lane 1,
uPA standard; lane 2, tPA standard; Lane 3, baseline (control); Lane 4, culture
with E2; lane 5, culture with ICI 182,780; lane 6, culture with the combination
of E2 and ICI 182,780; lane 7, uPAIPAI-1 complex standard; lane 8, tPAJPAI-1
complex standard. (B) uPAactvity was measured by chromogenic assay
from the same samples of CM
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Effects of exogenously added uPA on S30 and BC-2
cell growth
We have previously shown that S30 and BC-2 cells are growth
inhibited by 10-l-104 M concentrations of E, (Jiang and Jordan.
1992; Levenson et al, 1997). The fact that E, simultaneously
inhibits endogenous uPA synthesis and activity while having no
effect on uPAR prompted us to examine whether exogenous addi-
tion ofintact uPA could (a) exert any effect on proliferative behav-
iour of S30 and BC-2 cells; and (b) reverse the inhibitory effect of
E2 on growth. We performed a series ofexpenrments using various
concentrations of uPA in a range from 10 nm to 5000 nm. The
proliferative effect of added uPA was not different from that of
untreated control cells at days 2, 4 and 6 (data not shown). In
combination experiments with various concentrations of E,, uPA
in 106 M (1000 nM) was not able to reverse the E,-inhibitory effect
on cell growth (Figure 5).
To dissect possible reasons for added uPA failure, we performed
both zymography (Figure 6A) and ELISA (Figure 6B) using CM
from S30 cells treated with E,, uPA and combinations of E, and
uPA from day 2 (Fig 6). E, inhibited activity ofuPA. tPA and uPAJ
PAI-1. and tPA/PAI-1 complexes. Interestingly. the addition of
exogenous (lane 5) uPA alone resulted in its localization as both
free uPA and as uPA/PAI-l complex. When added to E, (lane 6),
the activity of uPA is decreased by both E2 and formation of the
uPAIPAI-1 complex. The uPAIPAI-l complex is also decreased
because of the inhibitory effect of E, on PAI-l levels. Samples
from this experiment were examined using ELISA to determine
the total (endogenous + exogenous) amount of uPA (Figure 6B).
Results showed that the addition of exogenous uPA incrased the
total amount ofuPA; however, when added to uPA. E,. was able to
decrease amount oftotal uPA below control levels.
BC-2
-- -- Control
.-... E2
--- Control
- E2+uPA
.5
3:
la
z
0
10 # ,
0 12 11 10 9 8 7 6
-log [ml E2
0 12 11 10 9 8 7 6
-log [M] E2
Figure 5 Effects of E2 and combinations of exogenousty added uPA and E2 on growth of S30 and BC-2 cells. Cells were treated with indicated concentrations
of E2 orcotbinatons of vanous concentrations of E2 and 10-6 M uPA for 6 days. The horizontal lines represent growth level in the absence ofcompounds
(control) foreach set ofexperiments
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respectve activities of uPA, tPA andcomplexes of uPAAPAI-1 and tPAtPAI-1.
The dilerent sampies were obtainedfrom cultures of S30 cels after 48 h of
treatmet with 109 M E2, 10-'M exogenously added uPA and conbiatons of
E2 and uPA in 4rreod cnceratons. Fron the left to theright lane 1,
tPA standard; Lane 2, uPA standard; lane 3, basekie (conrol); lane 4, culture
with E2; lane 5, cultre with exogenously added uPA; lane 6, cultre with the
conination of E2 and uPA lane 7, uPA/PAI-1 complex standard; lane 8,
tPUPAI-1 compex standard. (B) Total (etdogenous + exogenous) amunt of
uPA wasmeasured by EUSAfrom te sarne sanples of CM
DISCUSSION
Much knowledge has been gained in recent years ofthe prognostic
values of the components of the plasminogen-plasmin system in
breast tumour invasion. A number of studies have indicated that
high levels ofuPA, PAI-I and uPAR were found to beindependent
prognostic factors with respect to relapse-free and/or overall
survival, particularly in post-menopausal women (Gr6ndahl-
Hansen et al, 1992; 1995; 1997; Spyratos et al, 1992; Gohring et
al, 1995; Femo et al, 1996; Grondahl-Hansen et al, 1992). When
analysed with respect to the ER status of the tumour, no clear
answer was found: some found no correlation with the ER
(Duggan et al, 1995; Foekens et al, 1995; Grondahl-Hansen et al,
1997) whereas others (Grondahl-Hansen et al, 1992; Foekens et al,
1994; Ferno et al, 1996) demonstrated negative correlation
between high levels ofprognostic factors andER/PgR status ofthe
tumour. As to the hormonal regulation of the components of the
plasminogen-plasmin system in breast cancer cells in culture and
its ER-mediated nature, the findings are controversial, especially
for uPA. tPA but not uPA, PAI-1 or uPAR has been found to be
regulated by E, in breast cancer cells containing the ER (Butler et
al, 1979; Dickerman et al, 1989; Davis et al, 1995).
In the surgical specimens studied the expression ofuPA in breast
carcinomawas not inthe tumourcells butinthe myofibroblasts and
other stromal cells (Nielsen et al, 1996). However, this picure is far
from being clear. For example, xenografts of MDA-MB-231 cells
in nude mice produced tmours that, in in situ hybridization
studies, showed 'mRNA for human uPA in virtually all the cancer
cells' (Romer et al, 1994). In either case, the stromal cells or the
MDA-MB-231 cells do not express the ER. Thus, we wish to stress
that we are evaluating a model system of uPA regulation in the
laboratory that does not directly replicate the clinical situation in
breast cancer.
The availability of cells derived from MDA-MB-231 human
breast cancer cells, which stably express ER and contain high
levels of PAs, prompted us to examine the relationship between
ER content and hormonal regulation of expression of the compo-
nents ofthe plasminogen-plasmin system. To control at least three
steps ofE, regulation offinal PA activity, e.g. from genetranscrip-
tion to the enzyme activity, we concentrated on studying the regu-
lation of mRNA accumulation, intra- and extracellular protein
concentrations, and enzyme activities.
We herein report an observation that not only tPA but also uPA
and PAI-1 are regulated by E, in breast cancer cells transfected
with ER. Our results showed that uPA, tPA and PAI-I were down-
regulated by E, in tenms of mRNA and protein amount-activity
levels in both S30 and BC-2 cells. We also demonstrated that this
regulation is ER mediated because the pure anti-oestrogen ICI
182,780 was able to block the effect of E,. The observation that
both wild-type (S30 cells) and mutant ER (BC-2 cells) (data not
shown) did mediate the regulation ofuPA, PAI-1, tPA and uPAR in
a similar manner suggests that the mutation in the ligand-binding
domain ofthe receptor does not affect the E, effects.
Because the PA protein levels do not necessarily reflect the PA
activity, we performed zymographic analyses to examine the effect
of E2 on the activity of uPA and tPA in the media conditioned by
cells in the absence and pesence of 10-9 M E2. We found that E2
inhibits activity of uPA, tPA and PA/PAI-1 complexes. Thus, the
inhibitory effect ofE2 on PA activities in these cells occurs at any
level examined from mRNA to enzyme activity.
Ithasbeenreportedthat uPAR is presentin breastcancertissue but
not in normal breast tissue (Needham et al, 1987). uPAR isexpressed
in a variety of cancer cell lines and its synthesis is regulated by
growth factors, such as epidennal growth factor (EGF), trans-
forming-growth factors (TGF-1 and TGF-f2) and by the umour
prmoter phorbol myristate acetate (Lumd et al, 1991a, 1995). In its
native form uPAR is a glycolipid-anchored integral membrane
protein. Therefore, we were interested in examining uPAR levels in
cell extracts that represent potentially functional receptors compared
with water-soluble tion products of uPAR found in cytosols
(Gr6ndahl-Hansen et al, 1995). We found that our cells express
uPAR, and that its synthesis is not rgulated byE2.
A mitogenic effect of uPA has been demonstra in vitro in
different cell lines, both normal and neoplastic (Rabbai et al, 1990;
He et aL 1991; De Petro et al, 1994; luperello et al, 1996).
Conversely, the inhibition ofendogenously produced uPAby human
malignant melanomacells impairs cell proliferation (Kirchheimer et
aL 1989). It is believed that the mitogenic and growth factor activity
of uPA occurs throgh the amnotermnal fragment (AIT) of uPA,
containing the growth factor domain, which shares sucntures
homologous to the EGF, the TGF-a and the Krinkle domain. The
ATF is a binding site ofthe uPA molecule foruPAR. The activity of
uPA depends on the presence ofuPAR on the cells as its mitogenic
effect is selectively blocked by the addition of antibodies specific
for the receptor (De Petro et al, 1994).
If growth inhibition by E2 in ER transfectants is occurring
because E, inhibits production and activity of endogenous uPA,
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this effect should be reversible upon the addition of exogenous
uPA. However, the addition of exogenous uPA alone to culture
media did not have any growth stimulatory effects on S30 and
BC-2 cells, indicating that stimulatory effects of uPA varies with
different cell types. When added to E2, uPA was not able to block
the inhibitory effect of E2 on the growth. Tlere are several
possible explanations: (a) down-regulation of uPA by E, is an
upstream event ofinhibitory effect ofE2 ongrowth. Thus, replace-
ment of uPA would not affect El-mediated growth inhibition.
Parallel to our findings, Long et al showed (1996) that although
EGF and TGF-a exerted stimulatory effects on uPA expression in
S30 cells, neither of these growth factors was able to reverse the
suppressive action ofE, on growth ofthese cells. (b) Exogenously
added uPA is inactivatedbyforming auPA/PAI-l complex (Figure
6A). It is possible that recombinant tcuPA added to the culture is
more predisposed to complex formation with PAI-1 than endoge-
nous cellular uPA, which is secreted as a scuPA. This can explain
the detection of a large uPA/PAI-l band (Figure 6A, lane 5) and
subsequent absence of proliferative effect of uPA on these cells.
Tlne addition ofE, along with exogenous uPA to theculture affects
endogenous uPA levels as well as uPA/PAI-l complex formation
(Figure 6A, lane 6).
In sumnmay, we have shown that uPA, tPA and PAI-1 are regu-
lated by E, via the ER-mediated pathway in breast cancer cells
stably transfected with the ER inreasing levels of endogenous
uPA by transfection experiments with expression plasmids
containing the uPA gene might be useful in future investigations.
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